Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYPB - Cypress BioScience -- Ignore unavailable to you. Want to Upgrade?

To: muddphudd who wrote (501)	3/16/1999 9:12:00 PM
From: muddphudd	Respond to of 586

Hurray!!!! Finally. "Cypress Bioscience Inc. (Nasdaq:CYPB) announced today that the U.S. Food and Drug Administration (FDA) has approved the Prosorba(R) column for use in the treatment of moderate to severe rheumatoid arthritis (RA). " Should be an interesting day tomorrow!! Congrats to all CYPB shareholders.

To: muddphudd who wrote (501)	3/16/1999 9:15:00 PM
From: muddphudd	Respond to of 586

Cypress Holds Conference Call Cypress will hold a conference call March 17, 1999 at 4:15 p.m. EST to discuss FDA approval, its marketing plan for the Prosorba(R) column, the recent partnership with Fresenius AG and Cypress' 1998 financial results. Please call 800/937-4596 if you wish to participate. Phone lines will open at 4:05 p.m., EST. The call will include a brief report on the topics mentioned above followed by a question-and-answer period. Participants will include: Jay Kranzler, chief executive officer; Carl Bobkoski, president and chief operating officer; and R. Michael Gendreau, executive vice president, chief medical officer, and chief scientific officer. A taped replay will be available following completion of the conference call. The replay will be available for 48 hours beginning at 6:15 p.m. EST on Wednesday, March 17 and ending at 6:15 p.m. EST on Friday, March 19. To access playback of the call, telephone 800/633-8284 and enter the eight-digit reservation number 11989229. International callers may dial 619/812-6440, reservation number 11989229.